0001104659-24-040642.txt : 20240328
0001104659-24-040642.hdr.sgml : 20240328
20240328175727
ACCESSION NUMBER: 0001104659-24-040642
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240328
FILED AS OF DATE: 20240328
DATE AS OF CHANGE: 20240328
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gilad Oren
CENTRAL INDEX KEY: 0001929300
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 24800944
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
BUSINESS PHONE: 617-463-9385
MAIL ADDRESS:
STREET 1: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
4
1
tm2410009-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-28
0
0001781983
Aprea Therapeutics, Inc.
APRE
0001929300
Gilad Oren
3805 OLD EASTON ROAD
DOYLESTOWN
PA
18902
1
1
0
0
President, CEO
0
Common Stock
2024-03-28
4
A
0
6725
0.00
A
331495
D
Common Stock
1200
I
By daughter
Common Stock
600
I
By son
Stock Options (Right to Buy)
6.69
2024-03-28
4
A
0
26900
0.00
A
2024-03-28
Common Stock
26900
26900
D
These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
/s/ John Hamill, Attorney-in-Fact
2024-03-28